Brown DM - Search Results

1

KESTREL and KITE: 52-Week Results From Two Phase III Pivotal Trials of Brolucizumab for Diabetic Macular Edema.

Brown DM, Emanuelli A, Bandello F, Barranco JJE, Figueira J, Souied E, Wolf S, Gupta V, Ngah NF, Liew G, Tuli R, Tadayoni R, Dhoot D, Wang L, Bouillaud E, Wang Y, Kovacic L, Guerard N, Garweg JG. Brown DM, et al. Am J Ophthalmol. 2022 Jun;238:157-172. doi: 10.1016/j.ajo.2022.01.004. Epub 2022 Jan 14. Am J Ophthalmol. 2022. PMID: 35038415 Free article. Clinical Trial.

2

Relationship between optical coherence tomography-measured central retinal thickness and visual acuity in diabetic macular edema.

Diabetic Retinopathy Clinical Research Network; Browning DJ, Glassman AR, Aiello LP, Beck RW, Brown DM, Fong DS, Bressler NM, Danis RP, Kinyoun JL, Nguyen QD, Bhavsar AR, Gottlieb J, Pieramici DJ, Rauser ME, Apte RS, Lim JI, Miskala PH. Diabetic Retinopathy Clinical Research Network, et al. Among authors: brown dm. Ophthalmology. 2007 Mar;114(3):525-36. doi: 10.1016/j.ophtha.2006.06.052. Epub 2006 Nov 21. Ophthalmology. 2007. PMID: 17123615 Free PMC article. Clinical Trial.

3

Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study.

Brown DM, Michels M, Kaiser PK, Heier JS, Sy JP, Ianchulev T; ANCHOR Study Group. Brown DM, et al. Ophthalmology. 2009 Jan;116(1):57-65.e5. doi: 10.1016/j.ophtha.2008.10.018. Ophthalmology. 2009. PMID: 19118696 Clinical Trial.

4

A Phase IIIb study to evaluate the safety of ranibizumab in subjects with neovascular age-related macular degeneration.

Boyer DS, Heier JS, Brown DM, Francom SF, Ianchulev T, Rubio RG. Boyer DS, et al. Among authors: brown dm. Ophthalmology. 2009 Sep;116(9):1731-9. doi: 10.1016/j.ophtha.2009.05.024. Epub 2009 Jul 29. Ophthalmology. 2009. PMID: 19643495 Clinical Trial.

5

Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study.

Brown DM, Campochiaro PA, Singh RP, Li Z, Gray S, Saroj N, Rundle AC, Rubio RG, Murahashi WY; CRUISE Investigators. Brown DM, et al. Ophthalmology. 2010 Jun;117(6):1124-1133.e1. doi: 10.1016/j.ophtha.2010.02.022. Epub 2010 Apr 9. Ophthalmology. 2010. PMID: 20381871 Clinical Trial.

6

Long-term benefit of sustained-delivery fluocinolone acetonide vitreous inserts for diabetic macular edema.

Campochiaro PA, Brown DM, Pearson A, Ciulla T, Boyer D, Holz FG, Tolentino M, Gupta A, Duarte L, Madreperla S, Gonder J, Kapik B, Billman K, Kane FE; FAME Study Group. Campochiaro PA, et al. Among authors: brown dm. Ophthalmology. 2011 Apr;118(4):626-635.e2. doi: 10.1016/j.ophtha.2010.12.028. Ophthalmology. 2011. PMID: 21459216 Clinical Trial.

7

Primary endpoint results of a phase II study of vascular endothelial growth factor trap-eye in wet age-related macular degeneration.

Brown DM, Heier JS, Ciulla T, Benz M, Abraham P, Yancopoulos G, Stahl N, Ingerman A, Vitti R, Berliner AJ, Yang K, Nguyen QD; CLEAR-IT 2 Investigators. Brown DM, et al. Ophthalmology. 2011 Jun;118(6):1089-97. doi: 10.1016/j.ophtha.2011.02.039. Ophthalmology. 2011. PMID: 21640257 Clinical Trial.

8

The 1-year results of CLEAR-IT 2, a phase 2 study of vascular endothelial growth factor trap-eye dosed as-needed after 12-week fixed dosing.

Heier JS, Boyer D, Nguyen QD, Marcus D, Roth DB, Yancopoulos G, Stahl N, Ingerman A, Vitti R, Berliner AJ, Yang K, Brown DM; CLEAR-IT 2 Investigators. Heier JS, et al. Among authors: brown dm. Ophthalmology. 2011 Jun;118(6):1098-106. doi: 10.1016/j.ophtha.2011.03.020. Ophthalmology. 2011. PMID: 21640258 Clinical Trial.

9

Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III study.

Brown DM, Campochiaro PA, Bhisitkul RB, Ho AC, Gray S, Saroj N, Adamis AP, Rubio RG, Murahashi WY. Brown DM, et al. Ophthalmology. 2011 Aug;118(8):1594-602. doi: 10.1016/j.ophtha.2011.02.022. Ophthalmology. 2011. PMID: 21684606 Clinical Trial.

10

Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve-month outcomes of a phase III study.

Campochiaro PA, Brown DM, Awh CC, Lee SY, Gray S, Saroj N, Murahashi WY, Rubio RG. Campochiaro PA, et al. Among authors: brown dm. Ophthalmology. 2011 Oct;118(10):2041-9. doi: 10.1016/j.ophtha.2011.02.038. Epub 2011 Jun 29. Ophthalmology. 2011. PMID: 21715011 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

1,047 results

Search Page